热门资讯> 正文
Centessa股价在ONX 750的第一阶段发作性睡病研究中上涨10%
2024-09-10 23:41
- Shares of Centessa Pharmaceuticals (NASDAQ:CNTA) jumped 10% Tuesday after the company announced positive Phase 1 data for its narcolepsy drug candidate ORX750, with plans to rapidly advance it into Phase 2 testing.
- Centessa said that based on the interim Phase 1 data, it intends to initiate Phase 2 studies of ORX750 in patients with narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia beginning in Q4, according to a statement.
More on Centessa Pharmaceuticals
- Seeking Alpha’s Quant Rating on Centessa Pharmaceuticals
- Historical earnings data for Centessa Pharmaceuticals
- Financial information for Centessa Pharmaceuticals
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
